CL2014003569A1 - Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. - Google Patents
Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter.Info
- Publication number
- CL2014003569A1 CL2014003569A1 CL2014003569A CL2014003569A CL2014003569A1 CL 2014003569 A1 CL2014003569 A1 CL 2014003569A1 CL 2014003569 A CL2014003569 A CL 2014003569A CL 2014003569 A CL2014003569 A CL 2014003569A CL 2014003569 A1 CL2014003569 A1 CL 2014003569A1
- Authority
- CL
- Chile
- Prior art keywords
- fge
- iduronate
- sulfatase
- producing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666712P | 2012-06-29 | 2012-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003569A1 true CL2014003569A1 (es) | 2015-04-17 |
Family
ID=49778402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003569A CL2014003569A1 (es) | 2012-06-29 | 2014-12-29 | Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20140004097A1 (enExample) |
| EP (1) | EP2867367A4 (enExample) |
| JP (1) | JP2015523074A (enExample) |
| KR (1) | KR20150037908A (enExample) |
| CN (1) | CN104583414A (enExample) |
| AU (1) | AU2013282417A1 (enExample) |
| BR (1) | BR112014032544A2 (enExample) |
| CA (1) | CA2877492A1 (enExample) |
| CL (1) | CL2014003569A1 (enExample) |
| CO (1) | CO7240395A2 (enExample) |
| CR (1) | CR20140587A (enExample) |
| DO (1) | DOP2014000297A (enExample) |
| EA (1) | EA201492185A1 (enExample) |
| HK (2) | HK1209790A1 (enExample) |
| IL (1) | IL236324A0 (enExample) |
| IN (1) | IN2014DN11272A (enExample) |
| MX (1) | MX2015000188A (enExample) |
| PE (1) | PE20150603A1 (enExample) |
| PH (1) | PH12014502870A1 (enExample) |
| SG (1) | SG11201408755TA (enExample) |
| WO (1) | WO2014005036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| CN104662150B (zh) * | 2012-07-31 | 2018-07-10 | 比奥阿赛斯技术有限公司 | 脱磷酸化的溶酶体贮积症蛋白及其使用方法 |
| JP6586412B2 (ja) | 2013-03-13 | 2019-10-02 | バイオアシス テクノロジーズ インコーポレイテッド | ｐ９７のフラグメントおよびその使用 |
| ES2762672T3 (es) * | 2014-02-19 | 2020-05-25 | Bioasis Technologies Inc | Proteínas de fusión de P97-IDS |
| JP6785777B2 (ja) | 2015-02-05 | 2020-11-18 | アール．ピー． シェーラー テクノロジーズ エルエルシー | 活性化ホルミルグリシン生成酵素ならびにその生成方法及び使用方法 |
| KR20180063179A (ko) * | 2015-10-07 | 2018-06-11 | 조엘 후이젠가 | 인간의 노화에 따른 노쇠의 방어 및 회복을 위한 생체 경로의 복구 |
| ES2908470T3 (es) | 2015-11-09 | 2022-04-29 | Scherer Technologies Llc R P | Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos |
| CN109689191B (zh) * | 2016-07-25 | 2021-11-19 | 瑞普利金公司 | 交替切向流快速收获 |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008934A1 (en) | 1996-08-30 | 1998-03-05 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| DE60032349T2 (de) * | 1999-04-26 | 2007-07-12 | Genentech, Inc., South San Francisco | Zellenzuchtverfahren für glycoproteine |
| US6890736B1 (en) * | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
| SI2325302T1 (sl) * | 2003-02-11 | 2016-05-31 | Shire Human Genetic Therapies, Inc. | Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh |
| US20050019914A1 (en) * | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| WO2005113765A2 (en) * | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| EP2267024B1 (en) * | 2005-06-03 | 2012-05-09 | Ares Trading S.A. | Production of recombinant Il-18 binding protein |
| US7888101B2 (en) * | 2005-12-08 | 2011-02-15 | Amgen Inc. | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
| MX2010007846A (es) * | 2008-01-18 | 2010-10-05 | Biomarin Pharm Inc | Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas. |
| ES2725200T3 (es) * | 2009-10-09 | 2019-09-20 | Armagen Inc | Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC |
| US20130196410A1 (en) * | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| PL2593131T3 (pl) | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| US9150841B2 (en) * | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
-
2013
- 2013-03-14 US US13/829,811 patent/US20140004097A1/en not_active Abandoned
- 2013-06-28 JP JP2015520577A patent/JP2015523074A/ja active Pending
- 2013-06-28 KR KR1020157002278A patent/KR20150037908A/ko not_active Withdrawn
- 2013-06-28 MX MX2015000188A patent/MX2015000188A/es unknown
- 2013-06-28 CA CA2877492A patent/CA2877492A1/en not_active Abandoned
- 2013-06-28 WO PCT/US2013/048601 patent/WO2014005036A1/en not_active Ceased
- 2013-06-28 EP EP13810106.8A patent/EP2867367A4/en not_active Withdrawn
- 2013-06-28 CN CN201380042616.9A patent/CN104583414A/zh active Pending
- 2013-06-28 AU AU2013282417A patent/AU2013282417A1/en not_active Abandoned
- 2013-06-28 SG SG11201408755TA patent/SG11201408755TA/en unknown
- 2013-06-28 PE PE2014002540A patent/PE20150603A1/es not_active Application Discontinuation
- 2013-06-28 IN IN11272DEN2014 patent/IN2014DN11272A/en unknown
- 2013-06-28 BR BR112014032544A patent/BR112014032544A2/pt not_active IP Right Cessation
- 2013-06-28 HK HK15110518.5A patent/HK1209790A1/xx unknown
- 2013-06-28 EA EA201492185A patent/EA201492185A1/ru unknown
- 2013-06-28 HK HK15110043.9A patent/HK1209458A1/xx unknown
-
2014
- 2014-12-17 IL IL236324A patent/IL236324A0/en unknown
- 2014-12-17 CR CR20140587A patent/CR20140587A/es unknown
- 2014-12-22 PH PH12014502870A patent/PH12014502870A1/en unknown
- 2014-12-22 DO DO2014000297A patent/DOP2014000297A/es unknown
- 2014-12-26 CO CO14284195A patent/CO7240395A2/es unknown
- 2014-12-29 CL CL2014003569A patent/CL2014003569A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2867367A1 (en) | 2015-05-06 |
| PH12014502870A1 (en) | 2015-02-23 |
| CN104583414A (zh) | 2015-04-29 |
| CA2877492A1 (en) | 2014-01-03 |
| EA201492185A1 (ru) | 2015-10-30 |
| AU2013282417A1 (en) | 2015-01-29 |
| BR112014032544A2 (pt) | 2017-08-01 |
| WO2014005036A1 (en) | 2014-01-03 |
| MX2015000188A (es) | 2015-04-08 |
| DOP2014000297A (es) | 2015-04-15 |
| HK1209458A1 (en) | 2016-04-01 |
| IN2014DN11272A (enExample) | 2015-10-09 |
| JP2015523074A (ja) | 2015-08-13 |
| HK1209790A1 (en) | 2016-04-08 |
| IL236324A0 (en) | 2015-02-26 |
| CR20140587A (es) | 2015-04-06 |
| KR20150037908A (ko) | 2015-04-08 |
| US20140004097A1 (en) | 2014-01-02 |
| CO7240395A2 (es) | 2015-04-17 |
| EP2867367A4 (en) | 2016-02-24 |
| PE20150603A1 (es) | 2015-05-27 |
| SG11201408755TA (en) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014003569A1 (es) | Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. | |
| MY187874A (en) | Antibody formulations | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| MX2012007684A (es) | Modificacion covalente ligando dirigida de proteina. | |
| CL2012002416A1 (es) | Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano. | |
| CL2011002222A1 (es) | Metodo para preparar una proteina biologica condicionalmente activa; metodo para preparar un modificador condicionalmente activo de respuesta biologica. | |
| MX2019009191A (es) | Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas. | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| BR112013021134A2 (pt) | moduladores e métodos de uso | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| CO6440530A2 (es) | Formulaciones de caldo de fermentación | |
| WO2012045082A3 (en) | Engineered nucleic acids and methods of use thereof | |
| CL2014003568A1 (es) | Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante. | |
| BR112012032166A2 (pt) | composição, método para produzir um extrator e métodos para produzir um produto de álcool | |
| WO2012142591A3 (en) | Compositions, methods and uses for multiplex protein sequence activity relationship mapping | |
| MY170720A (en) | Antibody formulations | |
| AR089752A1 (es) | Anticuerpos anti-lrp5 y metodos de uso | |
| BR112012030678A2 (pt) | células-tronco da geleia de wharton nativa e sua purificação | |
| BR112013030321A2 (pt) | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. | |
| MX342270B (es) | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. | |
| EP2531597A4 (en) | MANIPULATED ENZYMES WITH METHIONIN GAMMA LYASE ENZYMS AND PHARMACOLOGICAL PREPARATIONS THEREOF | |
| NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| CL2013000237A1 (es) | Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo. | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV |